Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Author:

Sabe Marwa A.1,Claggett Brian2,Burdmann Emmanuel A.3,Desai Akshay S.2,Ivanovich Peter4,Kewalramani Reshma5,Lewis Eldrin F.2,McMurray John J. V.6,Olson Kurt A.5,Parfrey Patrick7,Solomon Scott D.2,Pfeffer Marc A.2

Affiliation:

1. Cardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

2. Cardiovascular Division, Heart and Vascular Center, Brigham and Women's Hospital, Boston, MA

3. Division of Nephrology, Department of Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil

4. Division of Nephrology, Department of Medicine, Northwestern University, Chicago, IL

5. Division of Research and Development, Amgen Inc, Thousand Oaks, CA

6. Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK

7. Division of Nephrology, Department of Medicine, Memorial University, St. John's, Newfoundland, Canada

Abstract

Background Although clear evidence shows that chronic kidney disease is a predictor of cardiovascular events, death, and accelerated coronary artery disease ( CAD ) progression, it remains unknown whether CAD is a predictor of progression of chronic kidney disease to end‐stage renal disease. We sought to assess whether CAD adds prognostic information to established predictors of progression to dialysis in patients with chronic kidney disease, diabetes, and anemia. Methods and Results Using the previously described Trial to Reduce Cardiovascular Events With Aranesp Therapy ( TREAT ) population, we compared baseline characteristics of patients with and without CAD . Cox proportional hazards models were used to assess the association between CAD and the outcomes of end‐stage renal disease and the composite of death or end‐stage renal disease. Of the 4038 patients, 1791 had a history of known CAD . These patients were older (mean age 70 versus 65 years, P <0.001) and more likely to have other cardiovascular disease. CAD patients were less likely to have marked proteinuria (29% versus 39%, P <0.001), but there was no significant difference in estimated glomerular filtration rate between the 2 groups. After adjusting for age, sex, race, estimated glomerular filtration rate, proteinuria, treatment group, and 14 other renal risk factors, patients with CAD were significantly more likely to progress to end‐stage renal disease (adjusted hazard ratio 1.20 [95% CI 1.01–1.42], P =0.04) and to have the composite of death or end‐stage renal disease (adjusted hazard ratio 1.15 [95% CI 1.01–1.30], P =0.03). Conclusions In patients with chronic kidney disease, diabetes, and anemia, a history of CAD is an independent predictor of progression to dialysis. In patients with diabetic nephropathy, a history of CAD contributes important prognostic information to traditional risk factors for worsening renal disease.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3